secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0001493152-23-043582
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma submits IND to FDA for GTB-3650 for CD33+ leukemia
---------------------------------------------------------------

- IND submitted for GTB-3650, a 2nd generation nanobody TriKE targeting CD33+ leukemia (relapsed/refractory AML and high-risk MDS).
- Interim CEO Michael Breen says company aims to move GTB-3650 into the clinic expeditiously in 2024.
- GTB-3650 is based on the proprietary TriKE NK cell engager platform licensed from University of Minnesota.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315223043582/0001493152-23-043582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315223043582/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-043582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer